Explaining the determinants of first phase HIV decay dynamics through the effects of stage-dependent drug action.

by James B Gilmore, Anthony D Kelleher, David A Cooper, John M Murray
Published 2013-01-01

HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.

by Hila Haskelberg, Damien V Cordery, Janaki Amin, Anthony D Kelleher, David A Cooper, Sean Emery, STEAL Study Group
Published 2014-01-01

Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.

by Allison Martin, Janaki Amin, Sean Emery, David Baker, Andrew Carr, David A Cooper, Mark Bloch, STEAL Study Group
Published 2011-01-01

Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.

by Amit C Achhra, Mark A Boyd, Matthew G Law, Gail V Matthews, Anthony D Kelleher, David A Cooper
Published 2014-01-01

The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.

by Karen Schneider, Chidi Nwizu, Richard Kaplan, Jonathan Anderson, David P Wilson, Sean Emery, David A Cooper, Mark A Boyd
Published 2013-01-01

Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional Silencing

by Chantelle Ahlenstiel, Catalina Mendez, Steven T H Lim, Katherine Marks, Stuart Turville, David A Cooper, Anthony D Kelleher, Kazuo Suzuki
Published 2015-01-01

Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia.

by Alexander Hoare, Stephen J Kerr, Kiat Ruxrungtham, Jintanat Ananworanich, Matthew G Law, David A Cooper, Praphan Phanuphak, David P Wilson
Published 2010-06-01

HIV dynamics linked to memory CD4+ T cell homeostasis.

by John M Murray, John Zaunders, Sean Emery, David A Cooper, William J Hey-Nguyen, Kersten K Koelsch, Anthony D Kelleher
Published 2017-01-01

The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.

by Steven N Reuland, Nathaniel B Goldstein, Katie A Partyka, David A Cooper, Mayumi Fujita, David A Norris, Yiqun G Shellman
Published 2011-01-01

Prevalence of self-reported comorbidities in HIV positive and HIV negative men who have sex with men over 55 years-The Australian Positive & Peers Longevity Evaluation Study (APPLE...

by Kathy Petoumenos, Robin Huang, Jennifer Hoy, Mark Bloch, David J Templeton, David Baker, Michelle Giles, Matthew G Law, David A Cooper
Published 2017-01-01

Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA.

by Yu Ming Paul Lam, Kristin L McBride, Janaki Amin, Damien V Cordery, Anthony D Kelleher, David A Cooper, Kersten K Koelsch
Published 2012-01-01

Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days.

by Mykola Pinkevych, Stephen J Kent, Martin Tolstrup, Sharon R Lewin, David A Cooper, Ole S Søgaard, Thomas A Rasmussen, Anthony D Kelleher, Deborah Cromer, Miles P Davenport
Published 2016-08-01

Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing

by Kazuo Suzuki, Shinichiro Hattori, Katherine Marks, Chantelle Ahlenstiel, Yosuke Maeda, Takaomi Ishida, Michelle Millington, Maureen Boyd, Geoff Symonds, David A Cooper, Seiji Okada, Anthony D Kelleher
Published 2013-01-01

Progressive activation of CD127+132- recent thymic emigrants into terminally differentiated CD127-132+ T-cells in HIV-1 infection.

by Sarah C Sasson, John J Zaunders, Nabila Seddiki, Michelle Bailey, Kristin McBride, Kersten K Koelsch, Kate M Merlin, Don E Smith, David A Cooper, Anthony D Kelleher
Published 2012-01-01

Restoration of CMV-specific-CD4 T cells with ART occurs early and is greater in those with more advanced immunodeficiency.

by Denise C Hsu, Stephen J Kerr, Thatri Iampornsin, Sarah L Pett, Anchalee Avihingsanon, Parawee Thongpaeng, John J Zaunders, Sasiwimol Ubolyam, Jintanat Ananworanich, Anthony D Kelleher, David A Cooper
Published 2013-01-01

Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART.

by Alan Winston, Rebekah Puls, Stephen J Kerr, Chris Duncombe, Patrick Li, John M Gill, Reshmie Ramautarsing, Simon D Taylor-Robinson, Sean Emery, David A Cooper, ALTAIR Study Group
Published 2015-01-01

The clinical characteristics of adults with rheumatic heart disease in Yangon, Myanmar: An observational study.

by Nan Phyu Sin Toe Myint, Ne Myo Aung, Myint Soe Win, Thu Ya Htut, Anna P Ralph, David A Cooper, Myo Lwin Nyein, Mar Mar Kyi, Josh Hanson
Published 2018-01-01

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomi...

by David A Cooper, Damien V Cordery, Roberto Zajdenverg, Kiat Ruxrungtham, Keikawus Arastéh, Frank Bergmann, José L de Andrade Neto, Joseph Scherer, Ricardo L Chaves, Patrick Robinson, study team
Published 2016-01-01

Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission.

by Mykola Pinkevych, Deborah Cromer, Martin Tolstrup, Andrew J Grimm, David A Cooper, Sharon R Lewin, Ole S Søgaard, Thomas A Rasmussen, Stephen J Kent, Anthony D Kelleher, Miles P Davenport
Published 2016-08-01

The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study

by Swe Swe Thit, Ne Myo Aung, Zaw Win Htet, Mark A. Boyd, Htin Aung Saw, Nicholas M. Anstey, Tint Tint Kyi, David A. Cooper, Mar Mar Kyi, Josh Hanson
Published 2017-08-01